Statements (56)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:physicist
|
| gptkbp:activeDuring |
recombinant DNA technology
somatropin |
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:availableSizes |
1.2 mg
0.6 mg 12 mg 6 mg 30 mg 48 mg 2.4 mg 24 mg 36 mg 4.8 mg |
| gptkbp:brand |
gptkb:Omnitrope
|
| gptkbp:clinicalTrials |
Phase 3
adults with growth hormone deficiency children with growth disorders |
| gptkbp:contraindication |
respiratory failure
active malignancy severe obesity |
| gptkbp:dosageForm |
injection solution
|
| gptkbp:drugInterdiction |
available online
corticosteroids subcutaneous absorption antidiabetic medications stimulates growth and metabolism |
| gptkbp:endOfLife |
approximately 2-4 hours
|
| gptkbp:formulation |
lyophilized powder
|
| gptkbp:healthcare |
storage instructions
injection technique side effects awareness importance of adherence |
| https://www.w3.org/2000/01/rdf-schema#label |
Omnitrope
|
| gptkbp:impact |
varies by patient
|
| gptkbp:is_monitored_by |
growth rate
blood glucose levels thyroid function |
| gptkbp:issuedBy |
subcutaneous injection
|
| gptkbp:mandates |
short stature
|
| gptkbp:marketedAs |
gptkb:Canada
gptkb:European_Union gptkb:United_States |
| gptkbp:numberOfStudents |
renal and hepatic pathways
|
| gptkbp:patentExpiration |
2023
|
| gptkbp:producedBy |
gptkb:Sandoz
|
| gptkbp:relatedTo |
endocrinology
pediatric medicine growth hormone therapy adult growth hormone deficiency |
| gptkbp:sideEffect |
headache
nausea joint pain injection site reactions |
| gptkbp:storage |
refrigerated
|
| gptkbp:usedFor |
growth hormone deficiency
|